SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ArQule, Inc. (ARQL)
An SI Board Since April 2003
Posts SubjectMarks Bans Symbol
545 40 0 ARQL
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
245i am holding, but not sure i see a compelling buy at these prices. i have been mopgcw-11/28/2005
244Another small insider buy, by Director Messenger. Not much, but it does double tuck-11/28/2005
243Legg: ARQL :Solid Quarter; Maintain Buy Rating 2005-07-28 10:55 (New York) Solimopgcw-10/28/2005
242[Identification of a Small Molecule That Induces Mitotic Arrest Using a Simplifituck-10/24/2005
241[HDAC inhibitors target the Rb-E2F1 pathway for apoptosis induction through actituck-10/21/2005
240I would have preferred to see this happen after Roche picks up and option or twoformer_pgs-9/27/2005
239ArQule to sell chemistry business: >>WOBURN, Mass.--(BUSINESS WIRE)--Septtuck-9/27/2005
238ArQule Announces Second Quarter Fiscal 2005 Results; Conference Call Scheduled TLee39-7/28/2005
237ARQL did a sale and leaseback of its buildings right after qtr end. This fool miLee39-7/21/2005
236Pride and Preclinicals By Karl Thiel (TMF Breaker Thiel) July 20, 2005 ArQulemopgcw-7/21/2005
235Maybe this explains ARQL's move today. Briefing.com completely misinformed Ian@SI-7/18/2005
234ArQule Announces Publication of Preclinical Data Demonstrating That Direct CheckLee39-7/18/2005
233more to keep one on the damn hook........ nature.com (link from stev-26 at yahscaram(o)uche-7/3/2005
232ArQule Initiates GLP Toxicology Testing with ARQ 197 Cancer Survival Pathway ComIan@SI-5/31/2005
231Michael Astrue buys 20K shares, open market. (eom)scaram(o)uche-5/24/2005
230ARQL poster session as reported by mh00034, who has posted here a couple of timetuck-5/15/2005
229With the caveat that I know nothing... >a) due to ARQL having developed someformer_pgs-5/4/2005
228Must be early Joyce, as I understood most of that post.nigel bates-5/4/2005
227What are the odds that the low spend on preclinical work is a) due to ARQL havintuck-5/4/2005
226>But all credit to them for publishing the information.< True enough. Haformer_pgs-5/3/2005
225But all credit to them for publishing the information.nigel bates-5/1/2005
224Interesting tidbit from the 10Q, with numbers in 1000s. "While we cannot sformer_pgs-4/30/2005
223LOTSOFF CAPITAL MANAGEMENT sec.gov Arqule Inc COMMON 04269E107 3119952 665Lee39-4/28/2005
222Thanks for taking the time to listen AND to pass content along. Saves time, evescaram(o)uche-4/21/2005
221Just finished listening to ARQL 20 minute earnings conference call - one of thIan@SI-4/21/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News